Van W. Knox

414 total citations
9 papers, 334 citations indexed

About

Van W. Knox is a scholar working on Physiology, Genetics and Physiology. According to data from OpenAlex, Van W. Knox has authored 9 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Physiology, 3 papers in Genetics and 3 papers in Physiology. Recurrent topics in Van W. Knox's work include Lysosomal Storage Disorders Research (7 papers), Adenosine and Purinergic Signaling (3 papers) and Neurogenetic and Muscular Disorders Research (3 papers). Van W. Knox is often cited by papers focused on Lysosomal Storage Disorders Research (7 papers), Adenosine and Purinergic Signaling (3 papers) and Neurogenetic and Muscular Disorders Research (3 papers). Van W. Knox collaborates with scholars based in United States, Australia and Italy. Van W. Knox's co-authors include Mark E. Haskins, Katherine P. Ponder, Thomas O’Malley, Meg M. Sleeper, Patricia A. O’Donnell, N. Matthew Ellinwood, Patricia O’Donnell, John R. Melniczek, Margaret A. Weil and Geoffrey K. Aguirre and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Molecular Therapy and Journal of the American Veterinary Medical Association.

In The Last Decade

Van W. Knox

9 papers receiving 327 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Van W. Knox United States 8 183 153 117 78 56 9 334
Chantelle McIntyre Australia 14 135 0.7× 197 1.3× 200 1.7× 74 0.9× 40 0.7× 18 411
Ayn Schneider United States 6 262 1.4× 250 1.6× 187 1.6× 107 1.4× 71 1.3× 7 459
Rita A. Monahan United States 5 104 0.6× 92 0.6× 83 0.7× 56 0.7× 19 0.3× 7 472
Elisa Masat Italy 10 96 0.5× 216 1.4× 233 2.0× 100 1.3× 16 0.3× 12 465
Kathleen Meyer United States 11 144 0.8× 219 1.4× 313 2.7× 64 0.8× 29 0.5× 23 469
Federico Mingozzi France 6 59 0.3× 198 1.3× 232 2.0× 53 0.7× 34 0.6× 6 352
Jason Pan United States 6 96 0.5× 68 0.4× 263 2.2× 55 0.7× 17 0.3× 20 454
Valentina Broshtilova Bulgaria 8 69 0.4× 77 0.5× 89 0.8× 36 0.5× 13 0.2× 44 347
Adan Chari Jirmo Germany 13 73 0.4× 47 0.3× 107 0.9× 97 1.2× 6 0.1× 35 487
M Chaâbouni Tunisia 12 97 0.5× 133 0.9× 108 0.9× 89 1.1× 9 0.2× 43 369

Countries citing papers authored by Van W. Knox

Since Specialization
Citations

This map shows the geographic impact of Van W. Knox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Van W. Knox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Van W. Knox more than expected).

Fields of papers citing papers by Van W. Knox

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Van W. Knox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Van W. Knox. The network helps show where Van W. Knox may publish in the future.

Co-authorship network of co-authors of Van W. Knox

This figure shows the co-authorship network connecting the top 25 collaborators of Van W. Knox. A scholar is included among the top collaborators of Van W. Knox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Van W. Knox. Van W. Knox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Ruane, Therese, Mark E. Haskins, Ping Wang, et al.. (2015). Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations. Molecular Genetics and Metabolism. 117(2). 157–163. 6 indexed citations
2.
Knox, Van W., et al.. (2015). Outcomes for dogs with primary hyperparathyroidism following treatment with percutaneous ultrasound-guided ethanol ablation of presumed functional parathyroid nodules: 27 cases (2008–2011). Journal of the American Veterinary Medical Association. 247(7). 771–777. 17 indexed citations
3.
Knox, Van W., Patricia A. O’Donnell, Yuli Liu, et al.. (2013). The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade. Molecular Genetics and Metabolism. 109(2). 183–193. 24 indexed citations
4.
Ponder, Katherine P., Thomas O’Malley, Ping Wang, et al.. (2012). Neonatal Gene Therapy With a Gamma Retroviral Vector in Mucopolysaccharidosis VI Cats. Molecular Therapy. 20(5). 898–907. 20 indexed citations
5.
Cotugno, Gabriella, Patrizia Annunziata, Alessandra Tessitore, et al.. (2010). Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene Transfer. Molecular Therapy. 19(3). 461–469. 60 indexed citations
6.
Herati, Ramin S., Van W. Knox, Patricia O’Donnell, et al.. (2008). Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Molecular Genetics and Metabolism. 95(3). 142–151. 40 indexed citations
7.
Ellinwood, N. Matthew, Marie‐Anne Colle, Margaret A. Weil, et al.. (2007). Bone marrow transplantation for feline mucopolysaccharidosis I. Molecular Genetics and Metabolism. 91(3). 239–250. 21 indexed citations
8.
Knox, Van W., Chandra M. Sehgal, & A. K. W. Wood. (2003). Correlation of ultrasonographic observations with anatomic features and radiography of the elbow joint in dogs. American Journal of Veterinary Research. 64(6). 721–726. 14 indexed citations
9.
Ponder, Katherine P., John R. Melniczek, Lingfei Xu, et al.. (2002). Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proceedings of the National Academy of Sciences. 99(20). 13102–13107. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026